Ryvu Therapeutics S.A.
WSE: RVU.WA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Warsaw Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Pawel Tadeusz Przewiezlikowski
- Employees
- 328
- Headquarters
- Kraków, Poland
- IPO year
- 2011
- Market cap
- PLN 536.4M
- Website
- https://www.ryvu.com
Loading RVU…
Loading profile data…Frequently asked questions about RVU
What does Ryvu Therapeutics S.A. (RVU.WA) do?
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid...
Where does RVU.WA trade?
Ryvu Therapeutics S.A. (RVU.WA) trades on the Warsaw Stock Exchange.
What sector is RVU.WA in?
Ryvu Therapeutics S.A. (RVU.WA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ryvu Therapeutics S.A.?
Pawel Tadeusz Przewiezlikowski is the chief executive officer of Ryvu Therapeutics S.A. (RVU.WA).
Where is Ryvu Therapeutics S.A. headquartered?
Ryvu Therapeutics S.A. is headquartered in Poland.
Does RVU.WA pay a dividend?
Ryvu Therapeutics S.A. (RVU.WA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RVU.WA go public?
Ryvu Therapeutics S.A. (RVU.WA) completed its initial public offering in 2011.